Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Heading back up to $3 and beyond? Last buying opportunity window closing now? Stay tuned for the continuing adventures of our unlikely superhero - Super Peregrine.
If taming cancer doesn't make you a superhero, what does? Pardon my exuberance.
Paul
I just added at 2.39.
Paul
When can we estimate the relapsed NSCLC patients trial will conclude? Is it by the end of 2011/beginning 2012? This trial was designed in consultation with the FDA to potentially result in early approval. Let's hope for blowout data. If we get it, our portfolios will bulge something wonderful.
Paul
I agree completely. The only reasonable course is to sell all of shares cheaply to idiots like me.
Thanks again,
Paul
Maybe I will get to buy more at less than $2. I have become a reverse cheerleader, because I want to buy more cheap. So, let's all talk more about cheap options, missing employees/contractors and the ever-popular, worthless Peregrine management.
Paul
Rapidly enrolling Phase II clinical trials are important steps in the evolution of Peregrine. I'm not sure why on this board so much energy if focused on peripheral matters. Are the trees more interesting than the forest?
Paul
Having read the report, what do you think the year end price could be?
Paul
Well said Thurly. We live in a murky imperfect world. However, Bavi may make it a little less imperfect. When/if it does, the murky potential of Peregrine will clear up considerably.
Paul
When we build it, they will come. Manipulation or no manipulation,
Paul
I believe, and of course I may be wrong, that 90 percent of the buyers and sellers of PPHM have no idea what it is. Those of us who frequent this board do; at least most of us do. So, when the share price goes up or down, based on the actions of those who really don't know PPHM at all, we are frustrated.
Our understanding may prove wrong, but if we are right, all this toing and froing will eventually turn our way.
Paul
I hope that sometime in the next two years someone will look back on this time and think, "If only I'd had the nerve to buy 10,000 shares of PPHM".
Paul
I too would rather just see the price go straight up, but if we drop below 2.50 I will add. I do love a bargain.
Paul
Before the split I had 5000 shares. I vowed never to buy again. However, as I continue to follow this process at Peregrine, I now find myself at 12000 post split shares. If the Peregrine news continues as it has for the last three years, I don't care how low the share price goes. I know better days are ahead, and soon.
Paul
I have not seen a sustained move up in this stock in years. This is really entertaining. I think we longs can be excused if we're exhilarated. I, for one, have a enormous capacity for exhilaration- let the good times roll!
Paul
Way way undervalued! Based on the pre-clinical and the "signalling" trials, there is an excellent chance that all four Bavi AC Phase II trials will pan out. That means lung, liver and pancratic cancers could be ripe for adding Bavi to the SOC.
Based on the Phase I hepc trials and the preclinical Ribavarin and Bavi testing, there is a good chance Bavi could muscle out the nasty interferon side of the hepc SOC.
We will have to wait six months to year to find out. However, if the results come in that we longs expect, this could be a very rewarding ride for those of us who had the cojones to buy as the share price fell lower and lower and lower. Wouldn't it be sweet if we were right.
Paul
I'm more than willing to take my chances with Cotara and Bavi. If the momentum players sell PPHM off back to 2.50, I will be happy to add to my bet. Peregine's management's clear efforts to push Cotara and Bavi over the finish line look really fine to me.
Paul
Which Bavi anti-cancer Phase II trial will complete first? And when? If the results are what we are looking for, we might just hit that $10 price target. Once there, a big bucks buyout could be possible.
Paul
It looks like Peregrine is finally achieving the recognition we longs think it deserves. Thank goodness some of have been buying over the last six months. We surely did average down, didn't we?
Paul
How much more news can we take? We're treating the worst cancer killers and taking on Hepatitis C.
Paul
I see the study involves Stage 4 patients. These people really need help. For their sakes I hope Bavi does a number on their cursed tumors.
Paul
No, I cant' see Bavi approved this year. The anti-PS nature of Bavi is, I believe, radically new. As much as I want Bavi to succeed, a Phase III trial is probably a good idea. If they chose to do it liver cancer patients, it could be a very quick Phase III.
Paul
I can't see the FDA approving Bavi without a Phase III trial. Bavi is just too revolutionary.
I could see the defence department stockpiling Bavi this year - not very likely but possible.
Cotara on the other hand is no longer revolutionary and it does addresses a sadly unmet need. Maybe Cotara will get the early approval.
All IMHO.
Paul
HCV, NSCLC, liver and pancreatic cancers - Peregrine is firing on all cylinders. I am more convinced than ever that this management is not a bunch of singles hitters. These guys are swinging for the upper deck. Way cool!
Paul
I wonder if the federal government's continuing budget resolution will affect the extension of the Peregrine defence department contract.
Paul
Good to see Peregrine continue to go after HCV. With limited resources Peregrine must really feel Bavi has a good shot at besting interferon's role in HCV treatment. This could give the share price a huge shot in the arm (pun intended) before the end of the year.
Paul
After the pancreatic trial notice, I gave up on trying to buy under $2 a share. Now I'm trying to buy at 2.43. Foolish foolish me.
Paul
Peregrine management continues to push Bavi at all the top cancer killers. These new trials are based in top US clinics. Kudos to PPHM. I may never get to buy my sub $2 shares, damn! If the price should ever get close to it, I may have to double down on this one.
Paul
Irons in the fire:
Cotara finally on the verge what would likely be a short Phase III trial and possible partnering,
Bavi in two fast moving Phase II NSCLC trials,
Bavi in government sponsored defence related research,
Mabufacturing and biosimilars going on at Avid, and
2C3, the better Avastin, being pushed hard by Affitech.
The odds of success were never very good, but they certainly do look better today than they have in years.
Paul
Is partnering Cotara a bad idea? In view of the relatively small number of GBM victims, could Peregrine sell this product directly through a small sales force and realize a much larger profit? Or has the time come that no real sales force is required? Just package kits and sell them directly from Tustin?
Paul
I hope you're all happy that I haven't been able to buy more shares at less the $2. I'm kind of happy myself.
Happhmy new year,
Paul
The forces pushing the stock up and their counterparts really do seem to be duking it out. Will we ever see sub $2 shares again? I really would like to add at that price.
Paul
As one of the resident cheer leaders, I hate to see the share price go down. However, I'd kind of like to add to my position at less than $2 a share one more time. Will the departing day traders oblige me by dumping more shares?
Paul
Two big SP runs up this month. Maybe PPHM will have a New Year's present for us. Somebody thinks so to the tune of 5 million shares bought during those two days.
Happy New Year to all! Even the inveterate, persistent dumpers who have helped us gobble up PPHM shares at bargain prices!
Paul
PPHM has not been this frisky in a long time. Apparently we have some new blood in the game. I hope they know something we don't.
Paul
Another run?!
For an obscure, underfunded company, Peregrine sure does get a A+ for ambition - clinical trials in brain cancer, lung cancer, liver cancer, HCV, as well as biodefence applications and contract mabufacturing!
Paul
What will tomorrow bring? I'm expecting continued weakness, but would be delighted to be wrong.
Paul
I find it interesting that the last two relatively big up moves in the share price were set off by Cotara news. Could Umass be basically right the a Cotara deal that would solidify Peregrine's fianancial stability is likely in the near term?
Paul
You don't sound happy. Give yourself a break; this could be the sound of PPHM finally getting you back in the black.
Paul
When PPHN partners for big bucks, they'll need the share to sell wont't they?
Paul